Opaleye Management’s Amicus Therapeutics FOLD Stock Holding History

Opaleye Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-320,800	Closed	-$3.06M	–	42
2021 Q3	$3.06M	Buy	+320,800	New	+$3.28M	0.57%	35

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Opaleye Management's FOLD Position: Q4 2021 in Review

Opaleye Management sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 320,800 shares — an estimated $3.06M sold.

Opaleye Management first reported a position in FOLD in Q3 2021 and held it in 1 quarter. The position peaked at $3.06M in Q3 2021. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

Opaleye Management reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
Opaleye Management sold 320,800 Amicus Therapeutics shares in Q4 2021, an estimated $3.06M.
Opaleye Management first reported a position in Amicus Therapeutics in Q3 2021 and held it in 1 quarter.
Opaleye Management's Amicus Therapeutics position peaked at $3.06M in Q3 2021.
224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.